Fenofibrate 145mg available for an empty stomach

Yuhan's first registration in July

Abbott products are about to be listed

Attention is focusing on whether GC Pharma, which has 145mg of non-reimbursement, will be involved in selling Abbott products.

 

Unlike conventional Fenofibrate 160mg tablets, the 145mg tablet market, which can be taken regardless of meals, is gradually heating up.

 

This is because Abbott products are also about to be listed after Yuhan Corporation listed related products for the first time in July.

 

In particular, Abbott is the original developer of Lipidil Supra, currently the No.

 

1 Fenofibrate, and attention is being paid to how Abbott's appearance will affect the market.

 

According to the industry on the 6th, Abbott received permission for "Lipidil NT" from the Ministry of Food and Drug Safety in June and is undergoing a registration process.

 

This product is a Fenofibrate 145mg tablet that can be taken regardless of diet.

 

Existing identical products include Fenowell 145mg and Neofeno 145mg of Yuhan Corporation, both of which are manufactured by Yuhan.

 

Fenowell 145mg was the only one on the list in July.

 

Fenofibrate, which is used to treat primary hyperlipidemia, is a 160mg tablet as the main formulation.

 

In particular, Lipidil Supra sold by GC Pharma is a blockbuster product that steadily generates more than 10 billion won every year, recording 16.5 billion won in out-patient prescriptions last year.

 

However, 160mg tablets have the inconvenience of having to be administered orally immediately after meals due to the problem of absorption in the stomach.

 

145mg has the advantage of being able to be taken regardless of food intake due to fast absorption in the gastrointestinal tract through improved formulation.

 

145mg has been released overseas before, but there was no limited product in Korea before the registration.

 

Abbott's Lipidil NT, which was approved this time, was licensed later than Yuhan and GC Pharma and classified as generic, but it is similar to the original product.

 

Abbott developed and supported the 145mg tablet itself, and Lipidil Supra, the original 160mg tablet, is also Abbott's original developer.

 

In the market, attention is being paid to the role of GC Pharma following the release of Lipidil NT.

 

This is because Abbott's original developer, Lippidil Supra, is sold by GC Pharma in Korea.

 

GC Pharma also co-sold Cholib, a 145mg compound of Fenofibrate & Micronized-Simvastatin, with Abbott in 2015.

 

The calculation of drug prices is also noteworthy.

 

The upper limit of the limited Fenowell 145mg, which was first registered in July, is 339 won.

 

This is because generic companies are also expected to feel burdened because they are relatively cheaper than existing 160mg tablets.